BioCentury | Aug 8, 2018
Distillery Therapeutics

Neurology

...Phase III testing to treat asthma. Novartis AG, Allergan plc and Norgine B.V. market Emselex darifenacin...
BioCentury | Jun 16, 2014
Company News

Merus Labs International, Dacha Strategic Metals deal

...by Aug. 15. Merus acquires and licenses pharmaceutical products, including overactive bladder (OAB) drug Emselex darifenacin...
...SIX:NOVN, Basel, Switzerland) in Canada and the EU, excluding France, Spain and Italy. Novartis acquired Emselex...
BioCentury | Jan 28, 2013
Company News

Merus Labs International, POA Pharma Scandinavia AB, Proximum d.o.o., SPCare Lda sales and marketing update

...Merus granted exclusive commercialization and distribution rights for Emselex darifenacin to POA Pharma in Denmark, Norway...
...$4.5 million. The companies did not disclose financial terms. Last July, Merus acquired rights to Emselex...
...SIX:NOVN, Basel, Switzerland) in Canada and the EU, excluding France, Spain and Italy. Novartis acquired Emselex...
BioCentury | Jul 16, 2012
Company News

Merus Labs International, Novartis sales and marketing update

...Merus acquired from Novartis rights to manufacture and market overactive bladder (OAB) drug Emselex darifenacin in...
...CHRM3 ; HM3 ) antagonist for OAB in the U.S., where it is marketed as Enablex...
BioCentury | Dec 5, 2011
Clinical News

Emselex regulatory update

...EMA's CHMP recommended updating the label for overactive bladder (OAB) drug Emselex darifenacin from Novartis to...
...Oct. 25, 2010). Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Emselex ( Enablex - U.S.) darifenacin...
BioCentury | Oct 25, 2010
Company News

Warner Chilcott, Novartis sales and marketing update

...Warner Chilcott completed its previously announced acquisition of the U.S. rights to commercialize Enablex darifenacin to...
...31, 2009). Warner Chilcott raised $500 million in notes last month to fund the acquisition. Enablex...
BioCentury | Sep 27, 2010
Finance

Regulatory milestones

...last week after acquiring sole rights in the U.S. to commercialize overactive bladder drug Enablex darifenacin...
BioCentury | Sep 27, 2010
Financial News

Warner Chilcott completes private placement of senior notes

...U.S. marketing rights from Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) for overactive bladder drug Enablex darifenacin. WIR...
BioCentury | Sep 25, 2010
Company News

Warner Chilcott acquires U.S. rights to bladder drug

...Chilcott plc (NASDAQ:WCRX) acquired sole rights in the U.S. to commercialize overactive bladder drug Enablex darifenacin...
...an offering of 7.8% senior notes due 2018. Warner Chilcott gained U.S. co-promotion rights for Enablex...
BioCentury | Aug 31, 2009
Company News

Warner Chilcott, P&G deal

...osteoporosis; and the co-promotion rights to Enablex darifenacin to treat overactive bladder (OAB). P&G co-promotes Enablex...
Items per page:
1 - 10 of 39